Skip to main content
Caplight Logo









Eliksa Therapeutics

Eliksa Therapeutics

Private
Doylestown, PennsylvaniaHealthcare & Life Scienceshttps://www.eliksa.com/

Last Round

Strategic

Oct 29, 2025

Company Overview

Eliksa Therapeutics is a biotechnology company that develops novel medicines for a range of debilitating diseases using the regenerative properties of amniotic fluid and amniotic membrane.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicineepidermolysis bullosaEBamniotic fluid secretomebiotechnologyrare diseaseorphan drugtissue repairbiological eye dropophthalmologycell-free therapyclinical trialbiologicsinflammation managementdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eliksa Therapeutics Comparables

Compare Eliksa Therapeutics with similar companies based on industry and business-model similarity.

Eliksa Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nova Anchora
73%
Castle Creek Biosciences
71%
RHEACELL GmbH & Co. KG
71%

Eliksa Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicOct 29, 2025
SeedJul 19, 2022

Key People

Founding team and executive leadership

Armen Karamanian, MD, PhD

Co-Founder & CEO

Founding Team

Eliksa Therapeutics Investors

Notable investors and investment history

Eliksa Therapeutics investors
InvestorRounds
Benjamin Franklin Technology PartnersSeed
Militia Hill VenturesSeed
BioAdvance CapitalSeed
DEBRA Research gGmbHStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Monthly visitors increased 141% MoM.

Eliksa Therapeutics Filings

Explore SEC and related filing metadata, where available.

Eliksa Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Eliksa Therapeutics's valuation, stock price, and market status.

Is Eliksa Therapeutics a public or private company?

Eliksa Therapeutics is a private company.

What is the current stock price of Eliksa Therapeutics?

Eliksa Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Eliksa Therapeutics worth (valuation)?

Valuation information for Eliksa Therapeutics is not publicly available.

Can I buy Eliksa Therapeutics stock?

Eliksa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Eliksa Therapeutics's last funding round?

Eliksa Therapeutics's most recent funding round was Seed on July 19, 2022.

Who are the main investors in Eliksa Therapeutics?

Key investors in Eliksa Therapeutics include Benjamin Franklin Technology Partners, Militia Hill Ventures.

Will Eliksa Therapeutics IPO soon?

No public IPO plans have been announced for Eliksa Therapeutics.

How can I track Eliksa Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Eliksa Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDoylestown, Pennsylvania
Employee Range6
Year Founded2021
Last FundingOct 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?